Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 1 12Phase 3 3Phase 1/2 3Phase 2/3 1

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 2Pathologic Complete Response 1Lymphoma, T-Cell 1Lymphoma 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Interventional × cc-486 × Clear all
NCT01757535 2025-07-08

QUAZAR AML-001

Celgene

Phase 3 Completed
472 enrolled 24 charts 1 FDA
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT03703375 2024-07-08

Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

Celgene

Phase 3 Active not recruiting
93 enrolled 19 charts
Lymphoid

Lymphoma, Lymphoma, T-Cell

NCT04173533 2024-05-14

AMADEUS

University of Birmingham

Phase 3 Active not recruiting
326 enrolled
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡